Tag: Aurora price target

Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?

For the last few months, there's been weakness in the cannabis sector. Investors were hoping for Canopy Growth and Aurora Cannabis to bring some relief.

This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

This year, Aurora Cannabis (ACB) has lost 30.5% of its stock value as of Thursday. Should you start to consider buying the stock? Jim Cramer doesn't think so.

Cantor Fitzgerald initiated coverage of six cannabis companies on Monday. Analyst Pablo Zuanic noted that several cannabis stocks have bottomed out.

For Aurora Cannabis (ACB), Canaccord lowered its target price from 13.50 Canadian dollars to 8.00 Canadian dollars with a “speculative buy” rating.

On Friday, Aurora Cannabis (ACB) traded at 4.99 Canadian dollars, down 14.3% for the month. Of the 16 analysts that follow ACB, 43.8% favor a “buy” rating.

HEXO announced a cut in its workforce amid changing market and regulatory conditions. The company wants to become profitable and attain long-term stability.

Amid sector weakness, Organigram stock is up 4.4% this month as of October 23. An upgrade and positive commentary appear to have raised its price.

On October 15, Aphria reported its Q1 earnings. Although Aphria's revenue came in lower than expected, its EBITDA and EPS beat analysts’ expectations.